Suggestions
Michael Muelly
Making machine intelligence for healthcare work
Michael C. Muelly, M.D., is the Co-founder and Chief Technology Officer (CTO) at IMVARIA Inc., a health tech company that develops AI-driven digital biomarker solutions.126 These solutions aim to help healthcare professionals make more accurate diagnoses and improve patient outcomes.1 IMVARIA was founded in 2019 by physician-engineers from Google and Stanford University.34 The company's Digital Biomarker Lab uses automated, machine-learning algorithm technology to transform clinical decision-making into data science.34
Muelly's background and roles:
- Education: He earned a Doctor of Medicine (MD) from Penn State University and studied Engineering Physics/Neural Engineering (though his PhD is incomplete).6 He completed a Residency in General Surgery at Penn State College of Medicine, followed by a Residency in Diagnostic Radiology and a Fellowship in Body MR Imaging at Stanford University.6 Muelly also holds a Bachelor of Science (B.S.) in Mathematics and Computer Science from the University of Pittsburgh and an Associate of Science (A.S.) in Accounting from the Community College of Allegheny County.6 He is certified in Diagnostic Radiology by the American Board of Radiology.6
- Experience: Before co-founding IMVARIA, Muelly was a Product Manager and Machine Learning Researcher at Google.1 He also has experience as a Clinical Assistant Professor of Radiology at Stanford University and as an Emergency Radiologist for Vision Radiology.6 Muelly's prior roles include Chief Medical Officer of GYANT, Healthcare AI Consultant at Dignity Health, and founder of ClariPACS LLC and Intradetect.6
Muelly's work at IMVARIA focuses on applying machine intelligence to data from sources like imaging or wearables to develop digital biomarkers.1 These biomarkers help healthcare professionals in the diagnosis of severe and rare diseases.1 IMVARIA's headquarters are in Berkeley, CA.34
IMVARIA has achieved significant milestones, including FDA authorization for its Fibresolve digital biomarker solution, which aids in the non-invasive diagnosis of lung fibrosis.45 In January 2025, IMVARIA received 510(k) clearance from the FDA for its ScreenDx solution, an AI-powered tool that assists clinicians in assessing for interstitial lung disease (ILD).7
